New Medicine Service Changes

Expansion of therapeutic areas included in the New Medicine Service from 1st September 2021

From 1st September 2021 the New Medicine Service (NMS) is expanded to include the following additional therapeutic areas:

  • Acute coronary syndrome (ACS)
  • Atrial fibrillation (AF)
  • Coronary heart disease
  • Epilepsy
  • Glaucoma
  • Gout
  • Heart failure
  • Hypercholesterolaemia 
  • Osteoporosis
  • Parkinson’s Disease
  • Stroke / transient ischemic attack
  • Urinary incontinence and retention

Existing therapeutic areas continue to be eligible as well.

The cap on completed NMS will increase from 0.5% to 1% of your monthly prescription volume and additional payment bandings* will be introduced.

The service will also be available to be offered to carers of patients and the parents or guardians of children with newly prescribed medication who could benefit from the service but where the patient is not able to provide informed consent themselves.

An additional Catch-up NMS* is being introduced to provide the best patient outcomes for patients that missed an NMS because of the pandemic.

The catch-up NMS will also support patients identified through the Pharmacy Quality Scheme (PQS) who have missed inhaler technique checks to optimise use of their inhaler.

*Further details to follow once published